

Elisabeth Brouwer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5101736/publications.pdf>

Version: 2024-02-01

195
papers

12,283
citations

38742

50
h-index

29157

104
g-index

196
all docs

196
docs citations

196
times ranked

13491
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	21.4	1,132
2	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	27.0	974
3	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
4	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
5	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 71.	30.5	443
6	Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 960-968.	6.7	427
7	Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. <i>Kidney International</i> , 1994, 46, 1-15.	5.2	366
8	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 638-641.	0.9	354
9	Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci. <i>PLoS Genetics</i> , 2011, 7, e1002004.	3.5	307
10	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.9	209
11	Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of) Tj ETQq1 1.0784314 rgBT /Ove	0.9	205
12	Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model.. <i>Journal of Experimental Medicine</i> , 1993, 177, 905-914.	8.5	195
13	Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R94.	3.5	179
14	Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. <i>Arthritis Research and Therapy</i> , 2012, 14, R222.	3.5	179
15	Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. <i>Kidney International</i> , 1994, 45, 1120-1131.	5.2	177
16	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017, 13, 578-592.	8.0	161
17	Immuno-miRs: critical regulators of T cell development, function and ageing. <i>Immunology</i> , 2015, 144, 1-10.	4.4	141
18	Common and different genetic background for rheumatoid arthritis and coeliac disease. <i>Human Molecular Genetics</i> , 2009, 18, 4195-4203.	2.9	128

#	ARTICLE	IF	CITATIONS
19	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
20	The periodontium of periodontitis patients contains citrullinated proteins which may play a role in <scp>ACPA</scp> (anti-€citruinated protein antibody) formation. <i>Journal of Clinical Periodontology</i> , 2012, 39, 599-607.	4.9	121
21	Aging disturbs the balance between effector and regulatory CD4+ T cells. <i>Experimental Gerontology</i> , 2014, 60, 190-196.	2.8	115
22	Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. <i>Genes and Immunity</i> , 2014, 15, 115-125.	4.1	111
23	Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Arthritis and Rheumatology</i> , 2014, 66, 1927-1938.	5.6	104
24	Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1297-1302.	0.9	99
25	Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis. <i>Medicine (United States)</i> , 2015, 94, e1542.	1.0	93
26	Regulation of Cytokine-Induced HIF-1 α Expression in Rheumatoid Synovial Fibroblasts. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 340-348.	3.8	92
27	Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Kidney International</i> , 1998, 53, 253-263.	5.2	89
28	The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. <i>Osteoporosis International</i> , 2011, 22, 1431-1439.	3.1	89
29	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1787-1788.	0.9	83
30	Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. <i>Rheumatology</i> , 2015, 54, 1397-1402.	1.9	83
31	Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-€associated systemic vasculitis: Anti-€proteinase 3-€mediated neutrophil activation is independent of the role of CD177-€expressing neutrophils. <i>Arthritis and Rheumatism</i> , 2009, 60, 1548-1557.	6.7	82
32	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
33	Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors. <i>Arthritis Care and Research</i> , 2017, 69, 1011-1019.	3.4	77
34	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. <i>JAMA Internal Medicine</i> , 2020, 180, 1295.	5.1	76
35	Glucocorticoid Dosages and Acute-€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	5.6	74
36	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1184-1190.	0.9	73

#	ARTICLE	IF	CITATIONS
37	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 769-775.	0.9	70
38	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	5.6	70
39	Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome. <i>Journal of Rheumatology</i> , 2016, 43, 383-387.	2.0	68
40	Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. <i>Rheumatology</i> , 2016, 55, 1143-1145.	1.9	63
41	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e15-e15.	0.9	62
42	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
43	Dual Role of miR-21 in CD4+ T-Cells: Activation-Induced miR-21 Supports Survival of Memory T-Cells and Regulates CCR7 Expression in Naive T-Cells. <i>PLoS ONE</i> , 2013, 8, e76217.	2.5	61
44	Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. <i>Arthritis Research and Therapy</i> , 2015, 17, 174.	3.5	59
45	Genetic variants in <i>IL15</i> associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1651-1657.	0.9	57
46	Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 134.	3.5	57
47	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
48	A Secreted Bacterial Peptidylarginine Deiminase Can Neutralize Human Innate Immune Defenses. <i>MBio</i> , 2018, 9, .	4.1	55
49	Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?. <i>Autoimmunity Reviews</i> , 2017, 16, 1071-1078.	5.8	54
50	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. <i>Arthritis and Rheumatology</i> , 2018, 70, 1366-1376.	5.6	54
51	Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. <i>Autoimmunity Reviews</i> , 2018, 17, 715-726.	5.8	53
52	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	3.9	52
53	Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments. <i>Arthritis Research and Therapy</i> , 2013, 15, R99.	3.5	49
54	The peptidylarginine deiminase gene is a conserved feature of <i>Porphyromonas gingivalis</i> . <i>Scientific Reports</i> , 2015, 5, 13936.	3.3	49

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
56	Antimyeloperoxidase-associated Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 987-994.	5.6	48
57	Expression and regulation of HIF-1 alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 61.	1.9	48
58	Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF- α Blocking Therapy: A Prospective Longitudinal Observational Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0122693.	2.5	46
59	Commentary: Periodontitis and Rheumatoid Arthritis: What Do We Know?. <i>Journal of Periodontology</i> , 2015, 86, 1013-1019.	3.4	45
60	Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis. <i>Scientific Reports</i> , 2017, 7, 6553.	3.3	45
61	Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. <i>Frontiers in Immunology</i> , 2019, 10, 83.	4.8	45
62	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. <i>Nature Genetics</i> , 2012, 44, 3-5.	21.4	44
63	Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients. <i>Scientific Reports</i> , 2016, 6, 26021.	3.3	44
64	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. <i>Scientific Reports</i> , 2017, 7, 5509.	3.3	44
65	Rheumatoid arthritis and periodontitis; a possible link via citrullination. <i>Anaerobe</i> , 2011, 17, 196-200.	2.1	43
66	Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 180-185.	0.9	43
67	Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. <i>Lupus</i> , 2012, 21, 959-968.	1.6	43
68	Low affinity TCR engagement drives IL-2 dependent post-thymic maintenance of naive CD4+ T cells in aged humans. <i>Aging Cell</i> , 2015, 14, 744-753.	6.7	43
69	Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. <i>Rheumatology</i> , 2019, 58, 1383-1392.	1.9	43
70	The effect of three years of TNF-alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. <i>Arthritis Research and Therapy</i> , 2012, 14, R98.	3.5	42
71	Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 1644-1650.	2.0	40
72	Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Immunology</i> , 2019, 10, 1981.	4.8	40

#	ARTICLE	IF	CITATIONS
73	Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 616-623.	3.4	40
74	Circulating CD4+CD161+ T Lymphocytes Are Increased in Seropositive Arthralgia Patients but Decreased in Patients with Newly Diagnosed Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e79370.	2.5	39
75	Quantifying Distribution of Flow Cytometric TCR-V β 2 Usage with Economic Statistics. <i>PLoS ONE</i> , 2015, 10, e0125373.	2.5	39
76	Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1164.	3.8	39
77	T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2015, 4, 117-122.	1.2	37
78	Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2017, 69, 694-702.	3.4	36
79	Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. <i>Rheumatology</i> , 2011, 50, 665-673.	1.9	35
80	Antibodies against <i>Porphyromonas gingivalis</i> in seropositive arthralgia patients do not predict development of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1277-1279.	0.9	35
81	Autoantibodies against citrullinated histone H3 in rheumatoid arthritis and periodontitis patients. <i>Journal of Clinical Periodontology</i> , 2017, 44, 577-584.	4.9	35
82	Neutrophil myeloperoxidase harbors distinct site-specific peculiarities in its glycosylation. <i>Journal of Biological Chemistry</i> , 2019, 294, 20233-20245.	3.4	35
83	EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 472-474.	0.9	34
84	Baseline predictors of response to TNF- α blocking therapy in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 290-298.	4.3	33
85	Lessons to be learned from periodontitis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 241-247.	4.3	33
86	Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF- α inhibitors. <i>PLoS ONE</i> , 2017, 12, e0177231.	2.5	33
87	Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1295-1301.	0.9	32
88	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152017.	3.4	32
89	Checks and Balances in Autoimmune Vasculitis. <i>Frontiers in Immunology</i> , 2018, 9, 315.	4.8	31
90	SF Treg cells transcribing high levels of Bcl-2 and microRNA-21 demonstrate limited apoptosis in RA. <i>Rheumatology</i> , 2015, 54, 950-958.	1.9	29

#	ARTICLE	IF	CITATIONS
91	Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. <i>Rheumatology</i> , 2022, 61, 1072-1082.	1.9	29
92	Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. <i>Clinical and Experimental Immunology</i> , 1996, 105, 321-329.	2.6	28
93	Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0132436.	2.5	28
94	Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status. <i>Journal of Rheumatology</i> , 2016, 43, 1008-1016.	2.0	27
95	Validation of the ACR-EULAR criteria for primary Sjögren's syndrome in a Dutch prospective diagnostic cohort. <i>Rheumatology</i> , 2018, 57, 818-825.	1.9	27
96	A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL40/Interleukin-13 Receptor 2 Axis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2327-2337.	5.6	27
97	Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3676-3684.	1.9	26
98	Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis. <i>PLoS ONE</i> , 2014, 9, e99685.	2.5	25
99	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016, 43, 182-186.	2.0	25
100	Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 752.	4.8	24
101	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	1.9	24
102	Towards precision medicine in ANCA-associated vasculitis. <i>Rheumatology</i> , 2018, 57, 1332-1339.	1.9	23
103	Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA. <i>Frontiers in Immunology</i> , 2019, 10, 1638.	4.8	23
104	Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire. <i>PLoS ONE</i> , 2013, 8, e55912.	2.5	23
105	Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. <i>PLoS ONE</i> , 2015, 10, e0137556.	2.5	23
106	Ageing-dependent decline of IL-10 producing B cells coincides with production of antinuclear antibodies but not rheumatoid factors. <i>Experimental Gerontology</i> , 2016, 75, 24-29.	2.8	22
107	Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF- α inhibitors: Facet joints vs. vertebral bodies. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 562-568.	3.4	22
108	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 222.	3.5	21
110	Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. <i>Journal of Autoimmunity</i> , 2021, 123, 102684.	6.5	20
111	Patient-tailored dose reduction of TNF- $\hat{\pm}$ blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 174-80.	0.8	20
112	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R108.	3.5	19
113	Clinical studies on bone-related outcome and the effect of TNF- $\hat{\pm}$ blocking therapy in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 259-268.	4.3	18
114	Reduced levels of cytosolic DNA sensor AIM2 are associated with impaired cytokine responses in healthy elderly. <i>Experimental Gerontology</i> , 2016, 78, 39-46.	2.8	18
115	Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2017, 19, 77.	3.5	18
116	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	3.9	18
117	A Review on the Value of Imaging in Differentiating between Large Vessel Vasculitis and Atherosclerosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 236.	2.5	18
118	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1302-1307.	0.9	17
119	The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age. <i>Immunity and Ageing</i> , 2019, 16, 22.	4.2	17
120	Lack of Association of C-C Chemokine Receptor 5 $\hat{\pm}$ 32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 2226-2231.	2.0	16
121	Regulatory CD4+ T-Cell Subsets and Anti-Citrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients?. <i>PLoS ONE</i> , 2016, 11, e0162101.	2.5	16
122	Renal ischemia/reperfusion injury contributes to renal damage in experimental anti-myeloperoxidase-associated proliferative glomerulonephritis. <i>Kidney International</i> , 1995, 47, 1121-1129.	5.2	15
123	Role for CaMKII Inhibition in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 706-711.	3.8	15
124	Changes in peripheral immune cell numbers and functions in octogenarian walkers – an acute exercise study. <i>Immunity and Ageing</i> , 2017, 14, 5.	4.2	15
125	CD27-CD38 ^{low} CD21 ^{low} B-Cells Are Increased in Axial Spondyloarthritis. <i>Frontiers in Immunology</i> , 2021, 12, 686273.	4.8	15
126	Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4958.	2.4	15

#	ARTICLE	IF	CITATIONS
127	Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 61-68.	0.8	15
128	Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. <i>Arthritis Research and Therapy</i> , 2015, 17, 108.	3.5	14
129	Safety of treatments for primary Sjögren's syndrome. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 513-524.	2.4	14
130	Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1400.	4.8	13
131	High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. <i>Rheumatology</i> , 2020, 59, 176-184.	1.9	13
132	Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e210-e210.	0.9	13
133	Vasculitis therapy refines vasculitis mechanistic classification. <i>Autoimmunity Reviews</i> , 2021, 20, 102829.	5.8	13
134	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	13
135	Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2529.	2.6	12
136	Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2017, 44, 292-296.	2.0	11
137	Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor- α Blocking Therapy in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2017, 44, 587-593.	2.0	11
138	Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e16-e16.	0.9	11
139	Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF- α inhibitors. <i>PLoS ONE</i> , 2018, 13, e0196281.	2.5	11
140	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. <i>Arthritis Research and Therapy</i> , 2015, 17, 158.	3.5	10
141	Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort: Table 1. <i>Rheumatology</i> , 2015, 54, 1333-1335.	1.9	10
142	Age-determined severity of anti-myeloperoxidase autoantibody-mediated glomerulonephritis in mice. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw202.	0.7	10
143	Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e263-e263.	0.9	10
144	Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in Giant Cell Arteritis. <i>Rheumatology</i> , 2021, , .	1.9	10

#	ARTICLE	IF	CITATIONS
145	Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis. <i>Frontiers in Immunology</i> , 2017, 8, 1377.	4.8	8
146	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	4.2	8
147	Methotrexate in Giant Cell Arteritis Deserves a Second Chance – A High-dose Methotrexate Trial Is Needed. <i>Journal of Rheumatology</i> , 2019, 46, 453-454.	2.0	8
148	Effect of age and sex on immune checkpoint expression and kinetics in human T cells. <i>Immunity and Ageing</i> , 2020, 17, 32.	4.2	8
149	What can negative temporal artery biopsies tell us?. <i>Rheumatology</i> , 2020, 59, 925-927.	1.9	8
150	Physical fatigue characterises patient experience of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 255-261.	0.8	8
151	Angiotensin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. <i>Arthritis Research and Therapy</i> , 2022, 24, 65.	3.5	8
152	Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis. <i>Rheumatology</i> , 2022, 62, 417-427.	1.9	8
153	Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miR-21 in T cells. <i>FEBS Journal</i> , 2017, 284, 555-567.	4.7	7
154	Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis. <i>PLoS ONE</i> , 2019, 14, e0211895.	2.5	7
155	Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohn's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8054.	2.6	7
156	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). <i>Rheumatology</i> , 2021, 60, 658-666.	1.9	7
157	Induction of an Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase(MPO) in Brown-Norway(BN), Lewis and Wistar Kyoto(WKY) Rat Strains. <i>Advances in Experimental Medicine and Biology</i> , 1993, 336, 139-142.	1.6	7
158	Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF- α blocking therapy. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 191-9.	0.8	7
159	Aortic involvement in giant cell arteritis. <i>Joint Bone Spine</i> , 2021, 88, 105045.	1.6	6
160	CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?. <i>Frontiers in Immunology</i> , 2021, 12, 654109.	4.8	6
161	Therapy response evaluation in large-vessel vasculitis: a new role for [18F]FDG-PET/CT?. <i>Rheumatology</i> , 2021, 60, 3494-3495.	1.9	6
162	Ageing enhances cellular immunity to myeloperoxidase and experimental anti-myeloperoxidase glomerulonephritis. <i>Rheumatology</i> , 2022, 61, 2132-2143.	1.9	6

#	ARTICLE	IF	CITATIONS
163	Distribution of monocytes subpopulations in the peripheral blood from patients with Behçet's disease - Impact of disease status and colchicine use. <i>Clinical Immunology</i> , 2021, 231, 108854.	3.2	6
164	Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 668-669.	0.9	6
165	Need and value of targeted immunosuppressive therapy in giant cell arteritis. <i>RMD Open</i> , 2022, 8, e001652.	3.8	6
166	Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al. <i>Arthritis Care and Research</i> , 2018, 70, 1275-1275.	3.4	5
167	Toward Reliable Uptake Metrics in Large Vessel Vasculitis Studies. <i>Diagnostics</i> , 2021, 11, 1986.	2.6	5
168	Vessel involvement in giant cell arteritis: an imaging approach. <i>Journal of Cardiovascular Surgery</i> , 2016, 57, 127-36.	0.6	4
169	Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort. <i>Lupus Science and Medicine</i> , 2021, 8, e000555.	2.7	3
170	OPO211â€¦ULTRASONOGRAPHY CAN POTENTIALLY BE THE FIRST CHOICE OF IMAGING IN SUSPECTED EXTRA-CRANIAL GCA. , 2019, , .		2
171	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	2.0	2
172	Encouraging data on rituximab in polymyalgia rheumatica. <i>Lancet Rheumatology</i> , The, 2021, , .	3.9	1
173	The value of inquiring about functional impairments for early identification of inflammatory arthritis: a large cross-sectional derivation and validation study from the Netherlands. <i>BMJ Open</i> , 2020, 10, e040148.	1.9	1
174	Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply. <i>Rheumatology</i> , 2022, 61, e185-e187.	1.9	1
175	Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.7	1
176	P1. Giant cell arteritis: B cells revisited. <i>Rheumatology</i> , 2014, 53, i12-i12.	1.9	0
177	I88.â€¦NOVEL THERAPEUTIC APPROACHES TO LARGE VESSEL VASCULITIS. <i>Rheumatology</i> , 2017, 56, .	1.9	0
178	351.â€¦EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. <i>Rheumatology</i> , 2019, 58, .	1.9	0
179	194.â€¦DISTRIBUTION OF MACROPHAGE SUBSETS IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
180	O26â€¦Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial. <i>Rheumatology</i> , 2019, 58, .	1.9	0

#	ARTICLE	IF	CITATIONS
181	272â€fAcute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. Rheumatology, 2019, 58, .	1.9	0
182	055.â€fHIGH SERUM ANGIOPOIETIN-2 LEVELS IDENTIFY LARGE VESSEL INFLAMMATION IN PATIENTS WITH POLYMYALGIA RHEUMATICA. Rheumatology, 2019, 58, .	1.9	0
183	FRI0275â€f...HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
184	FRI0266â€f...ABERRANT PD-1 AND VISTA EXPRESSION ON CD4+ TH-CELLS IN GIANT CELL ARTERITIS. , 2019, , .		0
185	FRI0381â€f...TROUGH SERUM DRUG LEVELS AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS PATIENTS ON LONG-TERM TREATMENT WITH TNF-Î± INHIBITORS. , 2019, , .		0
186	THU0330â€f...PREVALENCE OF RAYNAUDâ€™S PHENOMENON IN THE NORTHERN PARTS OF THE NETHERLANDS: AN EPIDEMIOLOGICAL STUDY OF THE LIFELINES COHORT. , 2019, , .		0
187	THU0329â€f...RED FLAG SIGNS OF SYSTEMIC SCLEROSIS ARE PREVALENT IN SUBJECTS WITH RAYNAUDâ€™S PHENOMENON IN THE GENERAL POPULATION AND MAY BE A PROXY FOR LUNG INVOLVEMENT. , 2019, , .		0
188	SAT0232â€f...DISTRIBUTION OF MACROPHAGE SUBSETS IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		0
189	SAT0228â€f...LEUKOCYTE DYNAMICS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA PATIENTS BEFORE, DURING AND AFTER TREATMENT. , 2019, , .		0
190	Pulmonary artery activity in Takayasuâ€™s arteritis, a role for [18F]FDG PET/CT?. European Heart Journal Cardiovascular Imaging, 2021, 22, 551-552.	1.2	0
191	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2018, , 1-23.		0
192	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2019, , 1573-1595.		0
193	PET imaging in vasculitis. , 2021, , .		0
194	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	2.0	0
195	Letter to the editor: Prevalence of connective tissue disease autoantibodies in a large longitudinal population-based cohort from the Netherlands. Autoimmunity Reviews, 2022, 21, 103063.	5.8	0